Adrenocortical carcinoma other imaging studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AAM}} {{MAD}} | {{CMG}}; {{AE}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Adrenal [[angiography]],[[venography]], positron emission tomography and MIBG may be used in the diagnosis of adrenocortical carcinoma. The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for diagnostic [[Computed tomography|CT]]. [[FDG]] [[PET scan|PET/CT]] is a useful modality for staging ACC and evaluating local recurrence. | Adrenal [[angiography]], [[venography]], [[positron emission tomography]] and MIBG may be used in the diagnosis of adrenocortical carcinoma. The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for diagnostic [[Computed tomography|CT]]. [[FDG]] [[PET scan|PET/CT]] is a useful modality for [[Cancer staging|staging]] ACC and evaluating local recurrence. | ||
==Other Imaging Studies== | ==Other Imaging Studies== | ||
Other Imaging studies that may be used in diagnosis of adrenocortical carcinoma are:<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1</ref> | Other Imaging studies that may be used in diagnosis of adrenocortical carcinoma are:<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1</ref> | ||
| Line 21: | Line 21: | ||
* The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for diagnostic [[Computed tomography|CT]]. | * The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for diagnostic [[Computed tomography|CT]]. | ||
* [[FDG]] [[PET scan|PET/CT]] has low [[sensitivity]] for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.<ref name="pmid16621901">{{cite journal| author=Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ et al.| title=Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 7 | pages= 2665-71 | pmid=16621901 | doi=10.1210/jc.2005-2612 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16621901 }}</ref> | * [[FDG]] [[PET scan|PET/CT]] has low [[sensitivity]] for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.<ref name="pmid16621901">{{cite journal| author=Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ et al.| title=Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 7 | pages= 2665-71 | pmid=16621901 | doi=10.1210/jc.2005-2612 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16621901 }}</ref> | ||
* | * The intensity of [[FDG]] uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor [[prognosis]].<ref name="pmid16621901" /> | ||
==References== | ==References== | ||
Revision as of 14:52, 26 September 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma other imaging studies On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma other imaging studies |
|
Risk calculators and risk factors for Adrenocortical carcinoma other imaging studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Adrenal angiography, venography, positron emission tomography and MIBG may be used in the diagnosis of adrenocortical carcinoma. The sensitivity of FDG PET/CT was 90% for the diagnosis of metastases as compared with 88% for diagnostic CT. FDG PET/CT is a useful modality for staging ACC and evaluating local recurrence.
Other Imaging Studies
Other Imaging studies that may be used in diagnosis of adrenocortical carcinoma are:[1]
- Adrenal angiography
- Adrenal venography
- PET scan (positron emission tomography scan)
- MIBG scan
- Bone scans are used to visualize bone metastasis
FDG PET/CT
- ACC presents as a large, heterogeneous mass with intense FDG uptake.[2]
- FDG PET/CT had a sensitivity of 100% and specificity of 88% in distinguishing benign from malignant lesions by using cutoff value above 1.45 for adrenal to liver maximum standardized uptake value (SUV).
- PET/CT cannot distinguish ACC from metastases, lymphoma, or pheochromocytoma due to the high metabolic activity of these tumors.[2]
- FDG PET/CT is a useful modality for staging ACC and evaluating local recurrence.
- Increased uptake of FDG may be seen in benign conditions including postoperative changes.
- No significant difference in accuracy was found between visual analysis, SUV analysis, and standardized uptake ratio (defined as the ratio of adrenal SUV activity to liver SUV activity) analysis.[3]
- The sensitivity of FDG PET/CT was 90% for the diagnosis of metastases as compared with 88% for diagnostic CT.
- FDG PET/CT has low sensitivity for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.[4]
- The intensity of FDG uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor prognosis.[4]
References
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1
- ↑ 2.0 2.1 Sundin A (2012). "Imaging of adrenal masses with emphasis on adrenocortical tumors". Theranostics. 2 (5): 516–22. doi:10.7150/thno.3613. PMC 3364557. PMID 22737189.
- ↑ Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H; et al. (2008). "[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes". J Clin Endocrinol Metab. 93 (6): 2358–65. doi:10.1210/jc.2008-0050. PMID 18397978.
- ↑ 4.0 4.1 Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ; et al. (2006). "Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma". J Clin Endocrinol Metab. 91 (7): 2665–71. doi:10.1210/jc.2005-2612. PMID 16621901.